Galectin-3 expression in uterine endometrioid adenocarcinoma: Comparison of staining in conventional tumor glands and in areas of MELF pattern myometrial invasion

International Journal of Gynecological Pathology

Volumn 29, Issue 6, 2010, Pages 555-561

  Stewart, Colin J R ^a   Crook, Maxine L ^a  

^a King Edward Memorial Hospital   (United States)

Author keywords

Endometrial carcinoma; Galectin 3; Immunohistochemistry; Invasion; MELF

Indexed keywords

CYTOKERATIN 7; GALECTIN 3;

ANATOMICAL VARIATION; ARTICLE; CANCER CELL; CANCER INVASION; CLINICAL ARTICLE; CYTOPLASM; ENDOMETRIUM CARCINOMA; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MYOMETRIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; UTERINE ENDOMETRIOID ADENOCARCINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; FEMALE; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 78149280141     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3181e4ee4ea     Document Type: Article

References (36)

1. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet 2005;366:491-505.
2. Sorosky JI. Endometrial cancer. Obstet Gynecol 2008;111: 436-7.
3. Salvesen HB, Akslen LA. Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS 2002;110: 673-89.
4. Clement PB, Young RH. Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 2002;9:145-84.
5. Murray SK, Young RH, Scully RE. Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcino-mas: a study of their frequency, associated diagnostic problems, and prognostic significance. Int J Gynecol Pathol 2003;22:324-33.
6. Stewart CJR, Brennan BA, Leung YC, et al. MELF pattern invasion in endometrial carcinoma: association with low-grade, myoinvasive endometrioid tumours, focal mucinous differentiation and vascular invasion. Pathology 2009;41:471-6.
7. Stewart CJR, Crook ML, Leung YC, et al. Expression of cell cycle regulatory proteins in endometrial adenocarcinoma: variations in conventional tumor areas and in microcystic, elongated and fragmented glands. Mod Pathol 2009;22:725-33.
8. Stewart CJR, Little L. Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition. Histopathology 2009;55: 91-101.
9. Prat J, Gallardo A, Cuatrecasas M, et al. Endometrial carcinoma: pathology and genetics. Pathology 2007;39:72-87.
10. Llobet D, Pallares J, Yeramian A, et al. Molecular pathology of endometrial carcinoma; practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol 2009;62:777-85.
11. Stewart CJR, Amanuel B, Grieu F, et al. KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasion. J Clin Pathol. In press.
12. Yang R-Y, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 2008; 10:e17.
13. Liu F-T, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer 2005;5:29-41.
14. Krzeslak A, Lipinska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 2004;9:305-28.
15. Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconj J 2004;19:543-9.
16. Califice S, Castronovo V, van den Brule F. Galectin-3 and cancer. Int J Oncol 2004;25:983-92.
17. Pieters RJ. Inhibition and detection of galectins. Chemobiochem 2006;7:721-8.
18. Brustmann H, Riss D, Naude S. Galectin-3 expression in normal, hyperplastic and neoplastic endometrial tissues. Pathol Res Pract 2003;199:151-8.
19. Van den Brule FA, Buicu C, Berchuck A, et al. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol 1996; 27:1185-91.
20. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet 2009;105:103-4.
21. Nakara S, Oka N, Raz A. On the role of galectin-3 in cancer apoptosis. Apoptosis 2005;10:267-75.
22. Nangia-Makker P, Balan V, Raz A. Regulation of tumor progression by extra-cellular galectin-3. Cancer Microenviron 2008;1:43-51.
23. Endo K, Kohnoe S, Tsujita E, et al. Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res 2005;25:3117-22.
24. Lotz MM, Andrews CW Jr, Korzelius CA, et al. Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon cancer. Proc Natl Acad Sci 1993;90: 3466-70.
25. Dancer JY, Truong LD, Zhai Q, et al. Expression of galectin-3 in renal neoplasms: a diagnostic, possible prognostic marker. Arch Pathol Lab Med 2010;134:90-4.
26. Mesenburger AS, Kramer MW, Hennenlotter J, et al. Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. World J Urol 2008;26:637-42.
27. Nakahara S, Raz A. Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway. Cancer Metastasis Rev 2007;26: 605-10.
28. Castronovo V, van den Brule FA, Jackers P, et al. Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 1996;179:43-8.
29. Van den Brule FA, Berchuck A, Bast RC, et al. Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer 1994;30A:1096-9.
30. Junking M, Wongkham C, Sripa B, et al. Decreased expression of galectin-3 is associated with metastatic potential of liver fluke-associated cholangiocarcinoma. Eur J Cancer 2008;44: 619-26.
31. Van den Brule FA, Waltregny D, Liu FT, et al. Alteration of the cytoplasmic/nuclear expression of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 2000;89: 361-7.
32. Mollenhauer J, Deichmann M, Helmke B, et al. Frequent downregulation of DMBT1 and galectin-3 in epithelial skin cancer. Int J Cancer 2003;105:149-57.
33. Lee J-W, Song SY, Choi J-J, et al. Decreased galectin-3 expression during the progression of cervical neoplasia. J Cancer Res Clin Oncol 2006;132:241-7.
34. Maquoi E, van den Brule FA, Castronovo V, et al. Changes in the distribution of galectin-1 and galectin-3 in human placenta correlates with the differentiation pathway of trophoblasts. Placenta 1997;18:433-9.
35. Stewart CJR, Crook ML, Doherty DA. Micro-anatomical variation in cellular proliferation in endometrial adenocarci-noma, and inverse correlation between Ki-67 and cytokeratin 7 expression. Histopathology. In press.
36. Hu M, Polyak K. Microenvironmental regulation of cancer development. Curr Opin Genet Dev 2008;18:27-34.